Guinea-Bissau Hepatitis B Vaccine Trial: Suspension or Cancellation – Uncertainty Remains

Confusion surrounds a controversial clinical trial in ⁣Guinea-Bissau. A Danish team, funded by the United States, is studying 14,000 newborns. Half received a hepatitis B vaccine at birth, while the others wait six⁣ weeks. This practice draws criticism in a country where nearly 20% of the population carries the virus.

Published: January 23, 2026 – 01:13

Reading ⁢time: 2 min

In Guinea-Bissau, announcements have come quickly: maintained, suspended, canceled? The Africa CDC (African Center for Disease Control and Prevention) held a press conference Thursday, January 22, to clarify the situation.